Articles & Announcements

FierceBiotech Features Livongo and Voluntis Partnership

FierceBiotech Features Livongo and Voluntis Partnership

“Livongo Health has struck a deal to offer Voluntis’ insulin dose recommendation medical device as part of its diabetes management service. The partners hope to improve treatment adherence and dose optimization by delivering automated recommendations to Livongo members’ smartphones.

Voluntis is contributing its FDA-cleared app, Insulia, to the alliance. The service enables clinicians to set up personalized treatment plans for their patients. Clinicians base the plan on their patient’s profile, insulin prescription and blood glucose targets. Based on this information and blood sugar readings, Insulia provides insulin dose recommendations and coaching messages to users, either via an iOS or Android app or a web portal.”

>> Read full article

MobiHealthNews Features Livongo and Voluntis Partnership

MobiHealthNews features the Livongo and Voluntis partnership

“Chronic disease management company Livongo is collaborating with Voluntis, the Paris, France-based company that develops companion apps for medical devices, to offer an integrated program, insulin delivery system and app for people with type 2 diabetes.

Members will have access to the Livongo for Diabetes Program with Voluntis’ Insulia, the diabetes management app that received both FDA approval and a CE Mark late last year. The app is designed for people treated with basal insulin and is classified as a prescription-only medical device.”

>> Read full article